Trial
NCT02432378
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Roswell Park Cancer Institute
Collaborators
AIM ImmunoTech Inc.; National Cancer Institute (NCI); University of Pittsburgh
Condition
Cancer of Ovary
Intervention
Cisplatin + celecoxib + DC vaccine
Why stopped
lack of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-19